Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of “Moderate Buy” from Analysts

Guardant Health, Inc. (NASDAQ:GH) has been given a consensus rating of “Moderate Buy” by the twenty-three research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twenty-one have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $106.8571.

Several analysts recently weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $90.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, December 15th. BTIG Research upped their price target on Guardant Health from $100.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Barclays raised their price objective on shares of Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Mizuho set a $135.00 target price on Guardant Health in a report on Friday, January 9th. Finally, Stifel Nicolaus boosted their price objective on shares of Guardant Health from $100.00 to $120.00 and gave the company a “buy” rating in a report on Friday, January 9th.

Insider Activity

In other news, insider Terilyn J. Monroe sold 8,571 shares of the stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the transaction, the insider owned 20,990 shares in the company, valued at $2,394,749.10. This represents a 28.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Medina Manuel Hidalgo sold 1,250 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $105.00, for a total value of $131,250.00. Following the sale, the director directly owned 797 shares of the company’s stock, valued at $83,685. This represents a 61.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 434,627 shares of company stock worth $45,592,052. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Guardant Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GH. V Square Quantitative Management LLC bought a new position in shares of Guardant Health in the 4th quarter valued at about $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health in the fourth quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Guardant Health during the 4th quarter worth $31,000. Elyxium Wealth LLC bought a new position in Guardant Health during the 4th quarter worth about $35,000. Finally, Parallel Advisors LLC increased its holdings in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the period. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Up 2.0%

Shares of Guardant Health stock opened at $104.85 on Friday. The firm has a market cap of $13.22 billion, a PE ratio of -32.66 and a beta of 1.63. Guardant Health has a 12-month low of $34.88 and a 12-month high of $120.74. The company’s fifty day simple moving average is $106.38 and its two-hundred day simple moving average is $83.76.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.